# An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Source: https://onco.cc/trials/nct05413018/  
OnCo record `nct05413018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CC-486 in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission is a phase 2 interventional study registered as NCT05413018 by Bristol-Myers Squibb, with 34 participants enrolled, started 2022-08-19 and due to reach its primary completion in 2025-10-31. Interventions recorded: CC-486.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05413018
- Phase: 2
- Setting: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission
- Sponsor: Bristol-Myers Squibb
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT05413018: https://clinicaltrials.gov/study/NCT05413018

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05413018.json